← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Attention Deficit-Hyperactivity Disorder

MONDO:0007743 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 40 citations openscientist · 60 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

ADHD is a highly heritable, multifactorial/polygenic neurodevelopmental disorder in which risk is distributed across many common variants (plus rarer larger-effect variants) rather than a single Mendelian locus, and the parent-to-child association is driven predominantly by genetic transmission.

UNANIMOUS INTEGRATED
genetic_factorpathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% the intergenerational transmission of risk for ADHD traits is largely explained by the transmission of genetic variants from parents to offspring rather than by genetic nurture.
Falcon frames ADHD as multifactorial and polygenic and, via the MoBa trio study, establishes that parent-child risk is genetic transmission rather than genetic nurture.
DOI:10.1038/s41380-022-01863-6
openscientist CONCORDANT 90% Its genetic architecture is complex and polygenic, with a mean heritability of 0.74-0.77 from twin studies, 12 genome-wide significant risk loci identified in the largest GWAS meta-analysis
OpenScientist quantifies the same polygenic architecture with twin-study heritability and GWAS loci, converging with Falcon on the polygenic model.
PMID:30478444, PMID:17718779

The core clinical phenotype is developmentally inappropriate inattention and hyperactivity-impulsivity, with childhood onset (symptoms before age 12), persistence of at least six months, cross-situational presence, and clinically significant functional impairment.

UNANIMOUS INTEGRATED
phenotypediagnosis
ProviderStanceScoreEvidence
falcon CONCORDANT 90% symptoms beginning before age 12, duration of at least 6 months
Falcon reports the shared DSM-5-TR / ICD-11 core requirements (onset before age 12, duration, cross-situational impairment) as the diagnostic backbone.
DOI:10.5498/wjp.v13.i5.138
openscientist CONCORDANT 90% developmentally inappropriate levels of inattention, hyperactivity, and impulsivity that persist for at least six months and cause clinically significant impairment in social, academic, or occupational functioning.
OpenScientist gives the same three-domain, impairment-based definition with childhood onset, matching Falcon's diagnostic framing.
PMID:26386541

ADHD pathophysiology centers on catecholamine (dopamine and norepinephrine) dysregulation within fronto-striatal-cerebellar circuits, supported by the mechanism of action of effective stimulant treatments and functional neuroimaging of executive/attention networks.

SINGLE INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% The core pathophysiology centers on catecholamine (dopamine and norepinephrine) dysregulation within fronto-striatal-cerebellar circuits.
OpenScientist develops the catecholamine-deficit hypothesis and fronto-striatal-cerebellar circuit model in depth, with fMRI and animal-model support.
PMID:15950012, PMID:22983386
falcon SILENT —
Falcon could not retrieve mechanistic/pathophysiology evidence in its run; it offers only a genetics-to-brain-regulation causal chain and explicitly flags the absence of a validated ADHD biomarker, never asserting the catecholamine or fronto-striatal-cerebellar circuit mechanism.

The symptom profile shifts with age: hyperactivity-impulsivity tends to decline from childhood into adulthood while inattentive symptoms remain comparatively stable, so older adolescents and adults present more prominently with inattention.

UNANIMOUS INTEGRATED
phenotypeprognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Cortese et al. note that hyperactive/impulsive symptoms tend to decrease more than inattentive symptoms, such that older adolescents/adults often present more prominently with inattentive symptoms.
Falcon reports the differential age trajectory of the two symptom domains, citing Cortese et al.
DOI:10.1002/wps.21374
openscientist CONCORDANT 85% Hyperactivity-impulsivity (HI) scores decline with age; inattention (IA) scores remain relatively stable
OpenScientist independently reports the same declining hyperactivity / stable inattention trajectory.
PMID:41716858

ADHD is common, with a worldwide-pooled childhood prevalence of about 5.29% and adult prevalence around 2.5%.

MAJORITY INTEGRATED
epidemiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% The ADHD/HD worldwide-pooled prevalence was 5.29%. This estimate was associated with significant variability
OpenScientist gives the canonical worldwide-pooled childhood prevalence (5.29%) and the ~2.5% adult figure from meta-analyses.
PMID:17541055, PMID:26386541
falcon PARTIAL 45% In a UK birth cohort, 3.0% of participants were classified with childhood ADHD problems at age 7
Falcon reports only fragmentary regional/cohort figures (UK cohort 3.0%, China GBD burden) and explicitly states a worldwide-pooled prevalence was not retrieved, so it overlaps on occurrence without the global 5.29% estimate.
DOI:10.1192/bjp.2023.90

First-line pharmacotherapy is psychostimulants (methylphenidate and amphetamines), with non-stimulants (atomoxetine, guanfacine, clonidine, viloxazine) as alternatives; stimulants show moderate-to-large short-term efficacy.

MAJORITY INTEGRATED
treatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Amphetamines (Hedge's g = 0.51, 95% CI = 0.08, 0.94), methylphenidate (0.38; 0.23, 0.54), and atomoxetine (0.30; 0.19, 0.40) were significantly more efficacious than placebo in improving QoL in people with ADHD
OpenScientist details first-line stimulant and non-stimulant efficacy with quantitative effect sizes and mechanisms.
PMID:38823477, PMID:34174276
falcon PARTIAL 40% A 2024 review highlights newer options beyond standard oral stimulants
Falcon treats standard oral stimulants and non-stimulants as background and instead emphasizes newer options; it does not report first-line stimulant efficacy effect sizes.
DOI:10.1089/cap.2024.0022

Newer non-drug and device-based treatment modalities - trigeminal nerve stimulation (TNS) and digital therapeutics - are emerging options for personalizing ADHD care.

MAJORITY LEAD
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% digital therapeutics, and trigeminal nerve stimulation (TNS) as new options to personalize ADHD care
Falcon foregrounds device/digital innovations (TNS, digital therapeutics, transdermal amphetamine patch, viloxazine ER) with trial-level detail.
DOI:10.1089/cap.2024.0022, DOI:10.1038/s41598-024-73934-3
openscientist PARTIAL 40% Physical exercises demonstrated the highest average effect size (Morris d = 0.93)
OpenScientist covers non-pharmacological interventions broadly (exercise, behavior therapy, neurofeedback, CBT) but does not address the specific device/digital innovations (TNS, digital therapeutics) Falcon emphasizes.
PMID:31629998, PMID:40398202

ADHD is associated with excess premature mortality and adverse long-term outcomes, including markedly reduced life expectancy in diagnosed adults and elevated accident/injury risk.

UNANIMOUS INTEGRATED
prognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Adults with diagnosed ADHD in UK primary care had reduced life expectancy of 6.78 years for males
Falcon reports reduced life expectancy in diagnosed adult ADHD and the broader medication benefit-risk picture (reduced injury/mortality during treated periods, long-term CVD risk with cumulative exposure).
DOI:10.1192/bjp.2024.199
openscientist CONCORDANT 80% Individuals with ADHD have significantly higher risk of multiple motor vehicle collisions (OR = 2.2) and collision fault (OR = 2.1)
OpenScientist agrees ADHD carries heightened premature mortality (chiefly via accidents/injuries) and elevated collision risk, converging with Falcon on excess mortality through a different measure.
PMID:25843156, PMID:33625499

ADHD shows extensive overlap with other psychiatric conditions and substance use, both clinically (anxiety, depression, substance use disorders) and at the level of shared genetic architecture.

MAJORITY LEAD
comorbiditygenetic_factor
ProviderStanceScoreEvidence
openscientist CONCORDANT 80% Psychiatric comorbidity (anxiety, depression, substance use disorders, personality disorders)
OpenScientist documents broad psychiatric comorbidity and multivariate shared genetic architecture across related disorders.
PMID:33625499
falcon PARTIAL 45% genetic correlation with cannabis use disorder was rg=0.57 (SE 0.04) and with cannabis use rg=0.20 (SE 0.04)
Falcon addresses comorbidity chiefly through shared genetics with cannabis use disorder (rg=0.57) rather than the broad clinical comorbidity profile.
DOI:10.1038/s44220-024-00277-3

Narrative

Overview

Both providers frame ADHD as a common, highly heritable, polygenic neurodevelopmental disorder defined by developmentally inappropriate inattention and hyperactivity-impulsivity with childhood onset and cross-situational impairment. OpenScientist is a comprehensive, mechanism-rich report (catecholamine hypothesis, fronto-striatal-cerebellar circuits, candidate genes, prevalence, treatment effect sizes, comorbidity, model organisms), whereas Falcon is a narrower, recency-weighted report focused on epidemiological burden, transmission genetics, diagnostic-criteria comparison, real-world medication outcomes, and treatment innovations, and it explicitly flags several domains (mechanism, phenotype frequencies, anatomy, global prevalence) as not retrieved in its run.

Agreement

The reports converge on the polygenic, transmission-dominant genetic architecture; on the core three-domain clinical phenotype with childhood onset and impairment; on the age trajectory in which hyperactivity-impulsivity declines while inattention persists; on stimulant/non-stimulant pharmacotherapy; and on ADHD carrying excess premature mortality and adverse long-term outcomes.

Divergence

OpenScientist uniquely supplies the catecholamine / fronto-striatal-cerebellar pathophysiology, the worldwide-pooled 5.29% childhood prevalence, candidate genes (DAT1/SLC6A3, DRD4, DRD5, 5HTT, HTR1B, SNAP25), quantitative treatment effect sizes, and broad psychiatric comorbidity. Falcon uniquely emphasizes device/digital treatment innovations (TNS, digital therapeutics, transdermal amphetamine patch, viloxazine ER), medication benefit-risk pharmacoepidemiology (reduced injury/mortality during treated periods vs long-term cardiovascular risk), reduced adult life expectancy, and cross-disorder genetics with cannabis use disorder. The differences are coverage/recency, not direct contradictions; where they overlap on prevalence Falcon reports only regional figures and states the global estimate was not retrieved.

Integration

Findings promoted to the disorder entry are the polygenic/transmission genetic model, the core symptom phenotype and diagnostic criteria, the catecholamine / fronto-striatal-cerebellar pathophysiology, the age-dependent symptom trajectory, the ~5.29% childhood / ~2.5% adult prevalence, first-line stimulant and non-stimulant pharmacotherapy, and the excess-mortality / adverse-outcome prognosis.

Not integrated (leads)

Retained as research leads rather than promoted: the emerging device/digital treatment modalities (TNS, digital therapeutics) and the shared-genetics / broad psychiatric comorbidity claims, which need further curation and reference verification before promotion to curated disease content.

Cross-provider synthesis of two independent ADHD deep-research reports: falcon (Edison Scientific Literature; narrower, recency-weighted) and openscientist (comprehensive, 15-domain). No direct contradictions were found; divergence is coverage/recency plus Falcon's explicit non-retrieval of mechanism, phenotype frequencies, anatomy, and global prevalence. best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets are intentionally left to the main curation pipeline pending fetch-reference verification of the underlying PMIDs/DOIs.